{"schema":"hottub-news/story/v1","story":"st_xigibnapwrwv6suros2a","title":"FDA Grants Priority Review to Fenebrutinib for Relapsing and Progressive MS","title_en":null,"outlets":3,"brief":null,"page":"https://hottub.news/stories/genentech-fda-grants-priority-review-to-fenebrutinib-nda-for-relapsing-xigibnapwr","count":3,"items":[{"id":"n_wbcnv6dusc62ilcjswya","seq":955969,"kind":"article","title":"FDA Grants Priority Review to Fenebrutinib for Relapsing and Progressive MS","url":"https://www.neurologyadvisor.com/news/fda-priority-review-fenebrutinib-relapsing-primary-progressive-multiple-sclerosis","published":"2026-09-30T15:54:00Z","seen":"2026-09-30T16:41:08Z","lang":"en","source":{"id":"neurologyadvisor.com","name":"neurologyadvisor.com","domain":"neurologyadvisor.com"},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"},{"id":"Q23304817","name":"fenebrutinib","type":"other"},{"id":"Q43319","name":"Mato Grosso do Sul","type":"other"}],"story":"st_xigibnapwrwv6suros2a","category":"health","category_p":0.5199999809265137,"sentiment":"neutral","tone":-0.38999998569488525,"political":0.1899999976158142},{"id":"n_e7ehovni3jlub3jbocxq","seq":951963,"kind":"article","title":"FDA Grants Priority Review to Fenebrutinib for Relapsing and Progressive MS","url":"https://www.empr.com/news/fda-priority-review-fenebrutinib-relapsing-primary-progressive-multiple-sclerosis","published":"2026-09-30T15:44:00Z","seen":"2026-09-30T16:21:53Z","lang":"en","source":{"id":"empr.com","name":"empr.com","domain":"empr.com"},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"},{"id":"Q23304817","name":"fenebrutinib","type":"other"},{"id":"Q43319","name":"Mato Grosso do Sul","type":"other"}],"story":"st_xigibnapwrwv6suros2a","category":"health","category_p":0.5199999809265137,"sentiment":"neutral","tone":-0.38999998569488525,"political":0.1899999976158142},{"id":"n_xigibnapwrwv6suros2a","seq":835447,"kind":"article","title":"Genentech: FDA Grants Priority Review To Fenebrutinib NDA For Relapsing And Primary Progressive MS","url":"https://www.rttnews.com/3695047/genentech-fda-grants-priority-review-to-fenebrutinib-nda-for-relapsing-and-primary-progressive-ms.aspx","published":"2026-09-30T05:37:00Z","seen":"2026-09-30T06:05:48Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q899140","name":"Genentech","type":"org"},{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"},{"id":"Q23304817","name":"fenebrutinib","type":"other"},{"id":"Q43319","name":"Mato Grosso do Sul","type":"other"}],"story":"st_xigibnapwrwv6suros2a","category":"health","category_p":0.3799999952316284,"category2":"science-technology","sentiment":"neutral","tone":-0.4300000071525574,"political":0.1899999976158142}]}